

RECEIVED

APR 2 3 2003

TECHCENSTERS 16000/2900

ase type a plus sign (+) inside this box → [+]

Substitute for form 1449A/PTO

Approved for use through 10/31/2001. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE					<u> </u>	Complete if Known					
						plication N			10/031,509		
STAT	ΓFΜ	FNT RY	PPI	CANT	Fil	ing Date		05/21/2002	2		
STATEMENT BY APPLICANT					Fir	st Named	Inventor	Eric Paul K	renning		
(use as many sheets as necessary)						oup Art Ur		1614			
	_				Ex	aminer Na	me	Not Yet As	signed		
Sheet 1 of 2					2 Att	orney Doc	ket Number	0702-0200	40		
				II C D	TENT DOC	NI IRAENITA					
Examiner	Cite	U.S. PATENT I					of Publication	on Pages C	Pages, Columns, Lines,		
Initials*	No.1	Number Kind Code ²		of Cited Document		of Ci	of Cited Document MM-DD-YYYY		Where Relevant Passages or Relevant Figures Appear		
										_	
								<u> </u>		<u>. </u>	
•					,,,				<u> </u>	-	
									·		
		i							· · · · · · · · · · · · · · · · · · ·		
				, <u> </u>							
		*		,						• _	
										_	
										<u> </u>	
						1			· · · ·	·	
				_			····			_	
										<u> </u>	
						_				-	
					· · · · · · · · · · · · · · · · · · ·				-		
			_								
	· · ·		_11	<u>.</u>							
			FC	REIGN	PATENT D	OCUMEN	ITS				
Examiner	Cite	Foreign Patent Document Kind			Name of Patentee or Applicant of Cited Document Neorx Corporation		of Publication	Pages, Column			
Initials	No.1					ited of Cite	d Document	Where Relevant or Relevant Figur		T ⁶	
5H						on 04/18/	1991	0	es repear		
	WO 96/29087			Center for Molecular Medi and Immunology		1996					
GM	-	WO 97/46099			Neorx Corporati		1997				
				_							
										<u> </u>	
		- 1					,		<u></u>		
Examiner Signature		(A	11.	0/1		Date		1/2	5/04		

Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 2Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.







JECH CENTER 1600/29(1)

Please type a plus sign (+) inside this box → +

Signature

Approved for use through 10/31/2001. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form	n 1449A/PTO					
				Complete if Known		
INFORM	nation c	DISCLOS	URE	Application Number	10/031,509	
STATEMENT BY APPLICANT				Filing Date	05/21/2002	
		1-711 11 12-11 1-7-11	N-780 R	First Named Inventor	Eric Paul Krenning	
(use as many sheets as necessary)				Group Art Unit	1614	
				Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	0702-020040	
		_				

-		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	Т						
sof.	140.	HAMMOND, P.J. et al., "Amino Acid Infusion Blocks Renal Tubular Uptake Of An Indium-Labelled Somatostatin Analogue", British Journal of Cancer, GB, London, Vol. 67, June 1993, pp. 1437-1439							
	•	BEHR T.M. et al. "Reduction of the Renal Uptake of Radiolabeled Monoclonal Antibody Fragments By Cationic Amino Acids And Their Derivatives", Cancer Research, Amer. Assoc. For Cancer Research, Vol. 55, No. 17, (1995), pp. 3825-3834							
		PIMM M. V. et al. "Prevention of Renal Tubule Re-Absorption of Radiometal (indium-111) Labelled Fab Fragment of a Monoclonal Antibody in Mice by Systemic Administration of Lysine"							
		BEHR T. M. et al "Reduction of Renal Uptake of Monoclonal Antibody Fragments By Amino Acid Infusion", J. Nucl. Med., Vol. 37, No. 5 (1996), pp. 829-833							
		KRENNING E. P. et al. "Radiolabelled Somatostatin Analogue(s) For Peptide Receptor Scintigraphy And Radionuclide Therapy", Annals of Oncology, Vol. 10, No. Suppl 2 (1999), pp. s23-s29							
54		BEHR T. M. et al. "Improved Prospects For Cancer Therapy With Radiolabeled Antibody Fragments And Peptides?", J. Nucl. Med. Vol. 37, No. 5, (1996), pp. 834-836							
		A /							
xaminer	1 /	Date Date							

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.